The Global Tyrosine Kinase Inhibitors Market is poised to grow strong during the forecast period 2017 to 2027. Some of the prominent trends that the market is witnessing include rising awareness about cancer diagnosis, increasing disease incidences and technological developments among high-quality products.
Based on Product, the market is categorized into Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors, BCR-ABL Tyrosine Kinase Inhibitors and Other Products.
Depending on Application, the market is segregated into Renal Cell Cancer, Lung Cancer, Chronic Myeloid Leukemia (CML), Breast Cancer and Other Applications.
Depending on Distribution Channel , the market is segregated into Independent Pharmacies, Online Pharmacies and Hospital Pharmacies.
This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.
The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc. The market data is gathered from extensive primary interviews and secondary research. The market size is calculated based on the revenue generated through sales from all the given segments and sub segments in the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.
This report provides data tables, includes charts and graphs for visual analysis.
Regional Analysis:
North America
Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- New Zealand
- Rest of Asia Pacific
Middle East
- Saudi Arabia
- UAE
- Rest of Middle East
Latin America
- Argentina
- Brazil
- Rest of Latin America
Rest of the World
Report Highlights:
- The report provides a detailed analysis on current and future market trends to identify the investment opportunities
- Market forecasts till 2027, using estimated market values as the base numbers
- Key market trends across the business segments, Regions and Countries
- Key developments and strategies observed in the market
- Market Dynamics such as Drivers, Restraints, Opportunities and other trends
- In-depth company profiles of key players and upcoming prominent players
- Growth prospects among the emerging nations through 2027
- Market opportunities and recommendations for new investments
Table of Contents
1 Market Outline
- 1.1 Research Methodology
- 1.1.1 Research Approach & Sources
- 1.2 Market Trends
- 1.3 Regulatory Factors
- 1.4 Product Analysis
- 1.5 Application Analysis
- 1.6 Strategic Benchmarking
- 1.7 Opportunity Analysis
2 Executive Summary
3 Market Overview
- 3.1 Current Trends
- 3.1.1 Rising Awareness about Cancer Diagnosis
- 3.1.2 Expansion of Research Areas in TKIs
- 3.1.3 Technological Developments Among High-Quality Products
- 3.1.4 Growth Opportunities/Investment Opportunities
- 3.2 Drivers
- 3.3 Constraints
- 3.4 Industry Attractiveness
- 3.4.1 Bargaining power of suppliers
- 3.4.2 Bargaining power of buyers
- 3.4.3 Threat of substitutes
- 3.4.4 Threat of new entrants
- 3.4.5 Competitive rivalry
4 Tyrosine Kinase Inhibitors Market, By Product
- 4.1 Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
- DATA TABLE Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Market Forecast to 2027 (US$ MN)
- 4.2 Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
- DATA TABLE Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors Market Forecast to 2027 (US$ MN)
- 4.3 BCR-ABL Tyrosine Kinase Inhibitors
- DATA TABLE BCR-ABL Tyrosine Kinase Inhibitors Market Forecast to 2027 (US$ MN)
- 4.4 Other Products
- DATA TABLE Other Products Market Forecast to 2027 (US$ MN)
5 Tyrosine Kinase Inhibitors Market, By Application
- 5.1 Renal Cell Cancer
- DATA TABLE Renal Cell Cancer Market Forecast to 2027 (US$ MN)
- 5.2 Lung Cancer
- DATA TABLE Lung Cancer Market Forecast to 2027 (US$ MN)
- 5.3 Chronic Myeloid Leukemia (CML)
- DATA TABLE Chronic Myeloid Leukemia (CML) Market Forecast to 2027 (US$ MN)
- 5.4 Breast Cancer
- DATA TABLE Breast Cancer Market Forecast to 2027 (US$ MN)
- 5.5 Other Applications
- DATA TABLE Other Applications Market Forecast to 2027 (US$ MN)
6 Tyrosine Kinase Inhibitors Market, By Distribution Channel
- 6.1 Independent Pharmacies
- DATA TABLE Independent Pharmacies Market Forecast to 2027 (US$ MN)
- 6.2 Online Pharmacies
- DATA TABLE Online Pharmacies Market Forecast to 2027 (US$ MN)
- 6.3 Hospital Pharmacies
- DATA TABLE Hospital Pharmacies Market Forecast to 2027 (US$ MN)
7 Tyrosine Kinase Inhibitors Market, By Geography
- 7.1 North America
- DATA TABLE North America Market Forecast by Countries to 2027 (US$ MN)
- 7.1.1 US
- 7.1.2 Canada
- 7.1.3 Mexico
- 7.2 Europe
- DATA TABLE Europe Market Forecast by Countries to 2027 (US$ MN)
- 7.2.1 France
- 7.2.2 Germany
- 7.2.3 Italy
- 7.2.4 Spain
- 7.2.5 UK
- 7.2.6 Rest of Europe
- 7.3 Asia Pacific
- DATA TABLE Asia Pacific Market Forecast by Countries to 2027 (US$ MN)
- 7.3.1 China
- 7.3.2 Japan
- 7.3.3 India
- 7.3.4 Australia
- 7.3.5 New Zealand
- 7.3.6 Rest of Asia Pacific
- 7.4 Middle East
- DATA TABLE Middle East Market Forecast by Countries to 2027 (US$ MN)
- 7.4.1 Saudi Arabia
- 7.4.2 UAE
- 7.4.3 Rest of Middle East
- 7.5 Latin America
- DATA TABLE Latin America Market Forecast by Countries to 2027 (US$ MN)
- 7.5.1 Argentina
- 7.5.2 Brazil
- 7.5.3 Rest of Latin America
- 7.6 Rest of the World (RoW)
- DATA TABLE RoW Market Forecast by Countries to 2027 (US$ MN)
- 7.6.1 South Africa
- 7.6.2 Others
8 Key Player Activities
- 8.1 Mergers & Acquisitions
- 8.2 Partnerships, Joint Venture's, Collaborations and Agreements
- 8.3 Product Launch & Expansions
- 8.4 Other Activities
9 Leading Companies
- 9.1 Tolero Pharmaceutical
- 9.2 Sanofi
- 9.3 QIAGEN
- 9.4 Pfizer
- 9.5 Onyx pharmaceuticals
- 9.6 Novartis
- 9.7 Merck
- 9.8 Johnson & Johnson
- 9.9 Incyte Corporation
- 9.10 GalaxoSmithKline
- 9.11 Exelixis
- 9.12 Chugai Pharmaceutical
- 9.13 Celgene Corporation
- 9.14 Bristol-Myer Squibb
- 9.15 Boehringer Ingelheim
- 9.16 Biogen Idec
- 9.17 Bayer Healthcare Pharmaceuticals
- 9.18 AstraZeneca
- 9.19 Array Pharmaceuticals
- 9.20 Advenchen Laboratories
チロシンキナーゼ阻害剤の世界市場：2019年～2023年
チロシンキナーゼ阻害剤市場：世界の業界分析、規模、シェア、成長、動向、2018～2026年の予測
世界の抗がん剤市場：細胞毒性薬（アルキル化剤、代謝拮抗剤）、標的薬物（モノクローナル抗体およびチロシンキナーゼ阻害剤）、ホルモン薬、地域別 - 産業分析、市場規模、シェア、成長、動向、予測（2017年～2025年）
世界の特発性肺線維症治療薬市場予測 (～2027年)：抗線維剤、チロシンキナーゼ阻害剤、抗炎症剤、免疫抑制剤、その他のモノクローナル抗体、イノベータードラッグ、未認可薬
世界の癌チロシンキナーゼ阻害薬市場 & 臨床パイプライン展望 2020年
腫瘍学における非チロシンキナーゼ阻害剤：2015～2025年
チロシンキナーゼ阻害薬の市場およびパイプラインの分析 (2015年)
